











Kakinen, Aleksandr, Javed, Ibrahim, Faridi, Ava, Davis, Thomas P. and Ke, Pu Chun. (2018) 
Serum albumin impedes the amyloid aggregation and hemolysis of human islet amyloid 
polypeptide and alpha synuclein. Biochimica et Biophysica Acta (BBA) - Biomembranes . 
 
Permanent WRAP URL: 
http://wrap.warwick.ac.uk/98815      
 
Copyright and reuse: 
The Warwick Research Archive Portal (WRAP) makes this work by researchers of the 
University of Warwick available open access under the following conditions.  Copyright © 
and all moral rights to the version of the paper presented here belong to the individual 
author(s) and/or other copyright owners.  To the extent reasonable and practicable the 
material made available in WRAP has been checked for eligibility before being made 
available. 
 
Copies of full items can be used for personal research or study, educational, or not-for-profit 
purposes without prior permission or charge.  Provided that the authors, title and full 
bibliographic details are credited, a hyperlink and/or URL is given for the original metadata 
page and the content is not changed in any way. 
 
Publisher’s statement: 
© 2018, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-
NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ 
 
A note on versions: 
The version presented here may differ from the published version or, version of record, if 
you wish to cite this item you are advised to consult the publisher’s version.  Please see the 
‘permanent WRAP url’ above for details on accessing the published version and note that 
access may require a subscription. 
 
For more information, please contact the WRAP Team at: wrap@warwick.ac.uk 
 
 1 
Serum albumin impedes the amyloid aggregation and hemolysis 
of human islet amyloid polypeptide and alpha synuclein 
Aleksandr Kakinen,†  Ibrahim Javed,† Ava Faridi,† Thomas P. Davis†§* and Pu Chun Ke†* 
†ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of 
Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia 





* Thomas P. Davis: thomas.p.davis@monash.edu and Pu Chun Ke: pu-chun.ke@monash.edu. 
  
 2 
ABSTRACT. Protein aggregation is a ubiquitous phenomenon underpinning the origins of a range 
of human diseases. The amyloid aggregation of human islet amyloid polypeptide (IAPP) and alpha 
synuclein (αS), specifically, is a hallmark of type 2 diabetes (T2D) and Parkinson’s disease 
impacting millions of people worldwide. Although IAPP and αS are strongly associated with 
pancreatic β-cell islets and presynaptic terminals, they have also been found in blood circulation 
and the gut. While extensive biophysical and biochemical studies have been focused on IAPP and 
αS interacting with cell membranes or model lipid vesicles, the roles of plasma proteins on the 
amyloidosis and membrane association of these two major types of amyloid proteins have rarely 
been examined. Using a thioflavin T kinetic assay, transmission electron microscopy and a 
hemolysis assay here we show that human serum albumin, the most abundant protein in the plasma, 
impeded the fibrillization and mitigated membrane damage of both IAPP and αS. This study offers 
a new insight on the native inhibition of amyloidosis. 
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Introduction  
Human islet amyloid polypeptide (IAPP) and alpha synuclein (αS) are two major classes of 
amyloid proteins serving both functional and pathogenic roles in biology. Specifically, monomeric 
IAPP assists insulin for glycemic control, while monomeric αS is thought to be associated with 
the modulation of neurotransmitter dopamine release, endoplasmic reticulum (ER)/Golgi 
trafficking, and synaptic vesicles [1]. The endogenous stabilization of IAPP is provided by insulin, 
physiological metal ions, low pH and zinc-mediated complexation of IAPP and C-peptide [2-8]. 
Likewise, transitions of αS from disordered monomers to partially folded intermediates and 
amyloid fibrils may be promoted by changes in local pH, ionic strength and temperature, as well 
as mutation [9, 10]. 
A large collection of literature has revealed that amphiphilic environments, such as cell membranes 
and lipid vesicles, can initiate electrostatic interactions between the N-termini of amyloid proteins 
and the anionic membranes [11-16], facilitated by hydrophobic interaction and hydrogen bonding 
between the interactants. Such interactions have been shown to convert the proteins from 
disordered monomers to α-helix and then β-sheet rich oligomers and protofibrils and, eventually, 
cross-beta amyloid fibrils. The oligomers and amyloid fibrils show a high propensity for 
partitioning into cell membranes, causing pore formation in a porin-like manner or extracting lipid 
content to compromise membrane fluidity [17-20]. The endpoints of such interactions range from 
generation of reactive oxygen species (ROS) to damage to ER, mitochondria, and DNA, followed 
by cell degeneration. Furthermore, it has been found that the aromatic side chains of LANFLVH, 
a fragment of IAPP, are nonessential in amyloid formation or membrane leakage [21], while 
cholesterol showed contrasting effects on IAPP toxicity and disruption to model membranes [22]. 
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In addition, inhibition of IAPP amyloidosis and increased IAPP resistance to protease degradation 
by copper (II) has also been reported [23].   
IAPP amyloid aggregation has been implicated as causative to the onset of type 2 diabetes (T2D). 
Likewise, the amyloid aggregation of αS into Lewy bodies or Lewy neurites is closely associated 
with motor symptoms and Parkinson’s disease. While IAPP fibrils and plaques are generally found 
in the extracellular space of pancreatic β-cell islets, Lewy bodies and Lewy neurites are located 
intracellularly. Regardless, oligomeric IAPP and αS have been widely acknowledged as the toxic 
species based on in vitro and animal studies [24, 25].  
IAPP is stored at millimolar concentrations in pancreas beta islets and readily fibrillates at 
micromolar concentrations [3]. Upon release into the bloodstream, IAPP is immediately exposed 
to a milieu of plasma proteins and lipids [26, 27]. Consequently, we have recently applied the 
concept of protein ‘corona’ [28, 29] originated from the field of nanomedicine for describing the 
structural transformation as well as the toxicity of IAPP in circulation [27]. Here the protein corona 
was rendered by model plasma proteins adsorbed on fibrillating IAPP or mature, hydrophobic 
IAPP fibrils through electrostatic and hydrophobic interactions as well as H-bonding, similarly to 
the formation of a protein corona adsorbed on nanoparticles [27, 29]. On the other hand, αS has 
recently been found in the heart and the gut, with the latter being hypothesized as a possible origin 
of the protein through the propagation of intestinal microbiota [30, 31]. Interestingly, human serum 
albumin (HSA), which accounts for 55% of all plasma proteins, has recently been found to possess 
a chaperone-like capacity against the amyloid aggregation of amyloid beta and transthyretin [32-
34], and this capacity of HSA was postulated to be realized through a ‘monomer-competitor’ 
mechanism for amyloid beta [35]. Accordingly, in the present study we examined the binding of 
HSA with IAPP and αS, two major types of amyloid proteins with significant health implications. 
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We evaluated the effects of their binding on the conformation and toxicities of the amyloid proteins 
using a thioflavin T (ThT, for fibrillization kinetics) assay and high-resolution transmission 
electron microscopy (TEM, for mesoscopic morphology), as well as a red blood cell (RBC) 
hemolysis assay (cell association and membrane leakage). Our study revealed a prolonged lag 
phase of IAPP and suppressed fibrillization of αS with the increase of HSA concentration. 
Additionally, the hemolysis assay demonstrated a protective effect of HSA on the toxicities of 
IAPP and αS towards RBCs. Together, these results offered a new perspective on the natural 
inhibition of IAPP and αS amyloidosis through the mediation of plasma proteins.  
Results and discussion 
Effects of HSA on IAPP and αS fibrillization 
The fibrillization kinetics of IAPP and αS in the presence of different HSA concentrations was 
examined using the amyloid specific dye ThT (Fig. 1). The lag phase of IAPP (50 µM) 
fibrillization at 37 ºC was approximately 20 min, followed by an elongation phase and a saturation 
phase after 2 h of incubation (Fig. 1A). In the presence of 10 µM HSA (5:1 molar ratio of IAPP to 
HSA) the lag phase was increased considerably to 4.2 h and the elongation phase to 8 h. With the 
HSA concentration increased to 50 µM (i.e., 1:1 IAPP to HSA molar ratio), the lag time was 
extended to 5.4 h while the elongation phase up to 11 h. At the highest tested HSA concentration 
of 100 µM (1:2 IAPP to HSA molar ratio), the lag time was further extended to 9 h while the 
saturation phase was reached after 13 h. This result demonstrates the deceleration effect of HSA 
on the fibrillization kinetics of IAPP, which could be due to the attraction between cationic IAPP 
and negatively charged HSA at physiological pH, or through hydrophobic interaction between the 
amyloidogenic region of IAPP (i.e. residues 20-29) and the hydrophobic domains of HSA to 
reduce IAPP availability for nucleation and elongation. This observation is consistent with the 
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aggregation inhibition of amyloid beta in the presence of HSA at comparable HSA/amyloid protein 
ratios [35].  
Our electron microscopy imaging confirmed the formation of IAPP amyloid fibrils after 17 h for 
the control (Figs. 2A,B) and for IAPP incubated with HSA (Figs. 2C-H). However, the presence 
of HSA altered the IAPP fibril morphology. Namely, at IAPP to HSA molar ratio of 5:1 the IAPP 
amyloid fibrils were stacked together into multi-fibrillar bundles (Figs. 2C,D). At a higher HSA 
concentration of 50 µM, IAPP fibrillated into large aggregates displaying significant intertwining 
(Figs. 2E,F). At excess HSA concentration of 100 µM we observed clear co-aggregation of fibrillar 
IAPP with HSA (Figs. 2G,H).  
In addition, our statistical analysis of the TEM images revealed that HSA exerted a concentration-
dependent influence on IAPP fibril length and rigidity (Figs. 4A-D). The persistence length (λ), a 
major indicator of rigidity [36], is 2,885 nm for (control) IAPP fibrils (Fig. 4A), which is 
comparable to that of beta lactoglobulin and amyloid-beta fibrils [37, 38]. The lowest HSA 
concentration did not significantly affect the persistence length or contour length of IAPP (Fig. 
4B). However, at 1:1 IAPP to HSA molar ratio we noted a three-fold softening of the amyloid 
fibrils (λ = 846 nm) and a narrower distribution of the fibril contour length (Fig. 4C). It should be 
acknowledged that the analysis of amyloid aggregates is not straightforward and may result in 
underestimated fibril contour length. Interestingly, the highest HSA concentration yielded more 
rigid fibrils (λ = 3,684 nm, or 27% increase from that of the control) (Fig. 4D). 
Understandably, the kinetics of αS fibril formation was markedly slower compared to IAPP, partly 
due to the much larger molecular weight of the neuronal protein (140 residues vs. 37 residues, or 
14,460 Da vs. 3,904 Da for αS vs. IAPP) as well as other different physicochemical attributes of 
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the amyloid proteins (sequence, charge, and hydrophobicity etc.). The lag phase of αS at 50 µM, 
37 ºC and with 500 rpm of shaking was up to 60 h, followed by a steep elongation phase up to 125 
h (Fig. 1B; Figs. 3A,B). In the presence of the lowest HSA concentration (10 µM, 5:1 IAPP to 
HSA molar ratio), αS fibrillization was markedly supressed according to the ThT fluorescence 
intensity, but was not entirely halted according to TEM imaging (Figs. 3C,D). At lower αS to HSA 
molar ratios (i.e. 1:1 and 1:2), no increase of ThT fluorescence (Fig. 1B) and no fibrils – according 
to TEM (Figs. 3E-H) – were observed up to 125 h of incubation. Due to the shaking applied to the 
samples to speed up fibril formation, the contour length analysis yielded relatively short fibrils 
only (Fig. 4E). The persistence length of αS fibrils was found to be 1,141 ± 9 nm, or 40% that of 
IAPP fibrils, whereas the presence of HSA increased the fibril persistence length up to 2,771 ± 3 
nm (Fig. 4E), comparable to that of IAPP control in the absence of the plasma protein.  
It has been proposed that the effect of (external) ligands on protein amyloid aggregation depends 
on the relative strength between protein-protein binding and protein-ligand binding [39]. In the 
case of IAPP, electrostatic attraction between IAPP (isoelectric point or pI: 8.9) [40] and HSA (pI: 
4.7) at equal molar concentration likely compromised the assembly of β sheets in amyloid fibril 
formation, resulting in both softer and shorter fibrils (Figs. 2E,F). This electrostatic interaction 
mediated the bundling of IAPP fibrils at the highest IAPP:HSA molar ratio (Figs. 2C,D), while 
caused IAPP fibrils to stiffen through the adsorption of an HSA corona at the highest plasma 
protein concentration (Figs. 2G,H). In the case of αS, HSA adsorption yielded a corona layer at 
the 5:1 αS:HSA molar ratio (Figs. 3C,D), while at lower αS:HSA molar ratios the repulsion 
between the like-charged neuronal protein (pI: 4.67) [41] and plasma protein as well as their 
hydrophobic interactions could interfere with the self-assembly of αS, thereby inhibiting αS fibril 
formation.   
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Ex vivo hemolysis of red blood cells 
One facile system for screening the toxicity of exogenous substances is the ex vivo hemolysis assay 
[42]. In this assay, the erythrocyte membranes serve as a model system for probing interactions 
between toxic compounds and the lipid bilayer. This model has been previously adopted to 
evaluate the endosomolytic behavior of cell-penetrating peptides, pH-responsive endosomolytic 
agents for cytosolic delivery [43], as well as other polymeric gene delivery systems [42, 44, 45]. 
Here we applied the hemolysis assay to examine the interactions of red blood cells (RBCs) with 
IAPP and αS w/o HSA (Fig. 5A). Evidently, both IAPP and αS demonstrated hemolytic activities 
against RBCs confirming their toxicity. Consistently with the ThT assay and TEM imaging, the 
hemolysis assay revealed a minor effect induced by the amyloid proteins mixed with HSA of 10 
µM (5:1 molar ratio). However, no hemolysis of RBCs was detected at both 1:1 and 1:2 amyloid 
proteins to HSA molar ratios alluding to the protective effect of the plasma protein. Using helium 
ion microscopy we observed noticeable damage to RBCs in DI water (Fig. 5B), or when the cells 
were exposed to IAPP (Fig. 5E), αS (Fig. 5I), or the amyloid proteins mixed with HSA of 10 µM 
(Figs. 5F,J). In those cases, the RBC cells appeared deformed from their usual biconcave-discoid 
shape, and at times were fully ruptured. No membrane damage was visible at higher HSA 
concentrations for either IAPP (Figs. 5G,H) or αS (Figs. 5K,L), while the RBC cell membranes 
displayed more rugged morphologies than the control likely resulting from HSA adsorption.  
Amyloid formation is a complex, multistep process, comprising the lag, elongation and saturation 
phases. Oligomeric species, formed during the lag process as an intermediate state, are postulated 
to be the most toxic of amyloidogenic proteins [3],  including IAPP and αS. Over the past decade, 
a number of molecular mechanisms have been proposed for amyloid oligomer toxicity, indicating 
the complex and dynamic nature of amyloidosis [46]. One of the widely accepted causes of 
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oligomeric toxicity is excessive formation of ROS during amyloid fibrillization. Despite free 
radicals are a normal component of cellular oxygen metabolism in mammals, free radical-
associated damage is an important factor in many pathological processes, including amyloid 
diseases. Albumin, on the other hand, has many known physiological functions, including the 
binding and transport of various endogenous and exogenous substances [47, 48]. Moreover, HSA 
has been found to be an important circulating antioxidant [49]. Thus, HSA can protect RBCs from 
hemolysis through its physical interaction with toxic oligomeric species, or its antioxidative 
property.  
Conclusion 
This study has generated several key findings concerning the interactions between plasma protein 
HSA and amyloid proteins IAPP and αS, an important aspect relevant to amyloidosis but has not 
been examined extensively in the literature. It has been shown that the major plasma protein HSA 
impeded the fibrillization of IAPP and αS, likely through competitive protein-protein and protein-
ligand interactions [39], consistent with the ‘monomer-competitor’ mechanism proposed for the 
chaperone-like activity of HSA against the aggregation of amyloid beta [35]. Specifically, HSA 
displayed a dose-dependent suppression of IAPP fibrillization kinetics, leading to delayed but not 
diminished amyloid fibril formation. In comparison, HSA completely inhibited the fibrillization 
of αS up to 125 h, also coupled with the fact that the neuronal protein, much larger in molecular 
weight but opposite in charge, fibrillates significantly slower than IAPP. In addition, we have 
found that HSA can protect RBCs from hemolysis incurred by the toxic IAPP and αS, which can 
be attributed to the protective mechanism of the plasma protein through its physical interaction 
with RBCs or its antioxidative property. 
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Materials and Methods  
Materials 
Human islet amyloid polypeptide (IAPP; 37 residues, 2-7 disulfide bridge, 3,904 Da, >95% pure 
by HPLC) and α-synuclein (αS; 140 residues, 14,460 Da, >95% pure by SDS-PAGE and mass 
spectrometry) were obtained in lyophilized monomeric form from AnaSpec, and prepared in Milli-
Q water (Millipore) at a stock concentration of 100 µM at room temperature immediately prior to 
use. Thioflavin T (ThT) dye and human serum albumin (HSA, 66,478 Da, ≥ 97% pure by gel 
electrophoresis) were both acquired from Sigma-Aldrich.  
Thioflavin T (ThT) assay 
IAPP and αS fibrillization in the presence or absence of HSA was analyzed by a ThT assay. For 
this 50 µM ThT dye, 50 μM of IAPP or αS monomers and 10 µM, 50 µM or 100 µM HSA were 
mixed, and the ThT fluorescence (read from bottom) was measured at 37 °C over 17 h for IAPP 
and 125 h (500 rpm linear shaking) for αS, using an EnSpire Multimode Plate Reader (Perkin 
Elmer; excitation/emission: 440 nm/485 nm) and a 96-well plate (Costar black/clear bottom). The 
ThT kinetic assay was performed in technical triplicate, and average spectra of 3 measurements 
were analyzed and presented by blank subtraction and normalized by IAPP/αS fluorescence at 
saturation. 
Transmission electron microscopy (TEM) and analysis 
IAPP and αS amyloids fibrillated (17 h for IAPP and 125 h for αS) alone or with different ratios 
with HSA were examined using high-resolution TEM. For this a 5 µL of amyloid-containing 
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solution was pipetted onto glow discharged (15 s) copper grids (400 mesh; ProSciTech), followed 
by 1 min of adsorption. Excess samples were then drawn off using filter paper and the grids were 
washed by Milli-Q water with the excess drawn off. Then the grids were stained with a drop of 
1% uranyl acetate for 30 s. The excess stain was drawn off and the grids were air dried. Imaging 
was performed by a Tecnai G2 F20 transmission electron microscope (FEI) operated at a voltage 
of 200 kV. Images were recorded using a Gatan UltraScan 1000 (2k×2k) CCD camera (Gatan, 
California, USA) and Gatan Microscopy Suite control software. 
Statistical analysis of amyloid fibrils 
The persistence length (λ) and contour length of IAPP and αS fibrils were analyzed using open 
source tracking and analysis software – FiberApp by a semi-automated fibril tracking procedure 
based on the A* pathfinding algorithm (minimal-cost path calculation or Dijkstra’s method) (Fig. 
4H) [36]. The persistence length reflects an intrinsic property of a polymer, denoting its rigidity 
and is mathematically defined by the bond correlation function (BCF) in 3D or 2D as the length 
over which angular correlations in the tangential direction decrease by a factor of e (Fig. 4G). Here 
the λ values of IAPP and αS fibrils were estimated using the average values derived from three 
methods: BCF, mean-squared end-to-end distance (MSED) and mean-squared midpoint 
displacement (MSMD). The contour length of a polymer corresponds to the end-to-end length 
along its contour/backbone (Fig. 4G). Statistical analysis was performed by tracking 97~336 fibrils 
in multiple TEM images per sample condition (Figs. 4A-F, n value).  
Ex vivo hemolysis assay 
IAPP, αS and their mixtures with HSA at different molar ratios were subjected to a hemolysis 
assay to assess the toxicities of the amyloid proteins to RBCs. Blood was collected from a healthy 
human donor after obtaining informed consent in accordance with the University of Melbourne 
 12 
Human ethics approval 1443420 and the Australian National Health and Medical Research 
Council Statement on Ethical Conduct in Human Research. The freshly drawn blood was 
centrifuged at 2 g for 5 min and RBCs were collected as pellets. The RBCs were washed three 
times with Dulbecco phosphate buffer saline (PBS) by centrifugal washings and diluted up to 5× 
with PBS. 100 µL of RBCs were incubated with 100 µL of each sample. The final sample 
concentration after mixing with RBCs was 50 μM for IAPP and αS, and 10 µM, 50 µM and 100 
µM for HSA. Samples containing αS, IAPP and their mixtures with HSA were pre-incubated in 
water for 2 days (500 rpm linear shaking) and 1 h at 37 °C, respectively, and mixed with PBS of 
1× in final concentration. After mixing with RBCs, the samples were incubated for 2 h at 37 ºC, 
centrifuged at 2 g for 5 min to pellet down the non-lysed RBCs, and hemolysis was measured by 
analyzing the absorbance of free hemoglobin leaked out of compromised RBCs in the supernatants 
at 541 nm (EnSpire Multimode Plate Reader, PerkinElmer). The RBCs incubated with PBS and 
50% water (1:1 cells in PBS with Milli-Q water) were used as 0% and 100% hemolysis controls. 











0% ,                                                                                                 (1) 
where Abt, Ab0 and Ab100 are absorbance values of the sample, the negative and the positive control, 
respectively. The hemolysis assay was performed in technical triplicate and average values of 3 
measurements were analyzed and presented. 
Helium ion microscopy 
RBCs treated by IAPP, αS and their combinations with HSA at different molar ratios were 
incubated overnight with 2.5% paraformaldehyde at 4 ºC and subsequently washed with gradient 
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concentrations of ethanol, i.e., 20%, 40%, 60%, 80% and 100%, with 2 h incubation at each 
gradient. A drop of RBCs in 100% ethanol was placed on a carbon tape and the sample 
morphologies were visualized by helium ion microscopy (Orion NanoFab, Zeiss, USA). 
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FIGURES AND CAPTIONS  
 
Figure 1. Effects of human serum albumin (HSA) on the fibrillization kinetics of (A) IAPP (50 
µM) and (B) αS (50 µM). IAPP fibrillization in presence of 10 µM (5:1 IAPP to HSA molar ratio), 
50 µM (1:1) and 100 µM (1:2) of HSA revealed a prolonged lag phase with the increase of HSA 
concentration. Fibrillization of αS was observed w/o the presence of HSA and with 10 µM (5:1 
molar ratio) of HSA. However, αS amyloid formation was inhibited in the presence of higher HSA 






Figure 2. Transmission electron microscopy imaging of IAPP fibrillization w/o and with HSA. 
(A, B) IAPP fibrils, (C, D) IAPP fibrillized with 10 µM HSA (5:1 IAPP to HSA molar ratio, 17 h 
incubation), (E, F) 50 µM HSA (1:1 ratio), and (G, H) 100 µM HSA (1:2 ratio). (I) 10 µM HSA 









Figure 3. Transmission electron microscopy imaging of αS amyloid fibril formation w/o and with 
HSA (A, B) αS control, (C, D) αS in the presence of 10 µM HSA, (E, F) αS in the presence of 50 
µM HSA, and (G, H) 100 µM HSA. (I) 10 µM HSA (equal to the concentration in the 5:1 ratio 





Figure 4. Contour length and persistence length (λ) analyses of IAPP (50 µM) (A-D) and αS (50 
µM) (E-F) fibrils incubated with 10 µM (5:1 ratio), 50 µM (1:1 ratio) and 100 µM (1:2 ratio)  HSA. 
The contour length of αS with HSA at 50 µM and 100 µM was not analyzed due to the lack of 
fibril formation. n: number of analyzed fibrils. (G) Schematic definitions of contour length and 
persistence length (λ) of the fibril. λ is defined as the length over which angular correlations in the 
tangent direction decrease by e times. Factor 2 in the formula accounts for 2D Euclidean geometry. 
Contour length corresponds to the end-to-end length of a fibril along its contour. (H) TEM image 
of IAPP amyloid fibrils and a tracked fibril contour, shown as a red line, by the FiberApp software. 
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Figure 5. (A) Determination of the in vitro toxicities of IAPP, αS and their combinations with 
HSA against red blood cells (RBCs) with an absorbance-based hemolysis assay. (B-L) 
Visualization of RBCs damaged by hemolysis using helium ion microscopy. Scale bars: 2 µm. 
